Get the Stockscreener App
10.02
1.62%
0.16
After Hours:
10.13
0.11
+1.10%
Beta Bionics Inc stock is traded at $10.02, with a volume of 2.04M.
It is up +1.62% in the last 24 hours and down -20.67% over the past month.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
See More
Previous Close:
$9.86
Open:
$9.93
24h Volume:
2.04M
Relative Volume:
1.64
Market Cap:
$444.71M
Revenue:
$100.25M
Net Income/Loss:
$-73.20M
P/E Ratio:
-5.9664
EPS:
-1.6794
Net Cash Flow:
$-56.22M
1W Performance:
-10.85%
1M Performance:
-20.67%
6M Performance:
-49.57%
1Y Performance:
-18.14%
1-Day Range:
$9.37
$10.40
1-Week Range:
$9.37
$11.92
52-Week Range:
$8.89
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
Name
Beta Bionics Inc
Sector
Industry
Phone
949-427-7785
Address
11 HUGHES, IRVINE
Compare BBNX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
10.02 | 437.61M | 100.25M | -73.20M | -56.22M | -1.6794 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | UBS | Buy |
| Jan-27-26 | Initiated | TD Cowen | Hold |
| Jan-09-26 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-21-25 | Resumed | Stifel | Buy |
| Oct-01-25 | Upgrade | Goldman | Neutral → Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| Jun-12-25 | Initiated | Lake Street | Buy |
| May-30-25 | Initiated | Goldman | Neutral |
| May-30-25 | Initiated | Wolfe Research | Outperform |
| Feb-24-25 | Initiated | BofA Securities | Buy |
| Feb-24-25 | Initiated | Lake Street | Buy |
| Feb-24-25 | Initiated | Leerink Partners | Outperform |
| Feb-24-25 | Initiated | Piper Sandler | Overweight |
| Feb-24-25 | Initiated | Stifel | Buy |
| Feb-20-25 | Initiated | Ladenburg Thalmann | Neutral |
| Feb-20-25 | Initiated | Robert W. Baird | Neutral |
View All
Beta Bionics Inc Stock (BBNX) Latest News
Beta Bionics Introduces Bionic Insights™ in Bionic ReportsTransforming How Clinicians Understand and Optimize Diabetes Care - The Manila Times
Beta Bionics, Inc. (NASDAQ:BBNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026 - Bitget
Beta Bionics, Inc. (NASDAQ:BBNX) Short Interest Update - MarketBeat
Beta Bionics (NASDAQ:BBNX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - PR Newswire
Aug Selloffs: Can Beta Bionics Inc grow without external funding2026 Volatility Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Insider Buy: Does Beta Bionics Inc have a competitive edge2026 Selloffs & Low Risk Growth Stock Ideas - baoquankhu1.vn
[SCHEDULE 13G/A] Beta... - Stock Titan
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - GlobeNewswire
Lake Street Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Shorts Report: Can Beta Bionics Inc deliver alphaMarket Activity Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
Inflation Data: Is Beta Bionics Inc a top pick in the sectorInsider Selling & Daily Profit Focused Screening - baoquankhu1.vn
Beta Bionics (NASDAQ:BBNX) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Bionics (BBNX) - marketscreener.com
ONGOING INVESTIGATION NOTICE: Faruqi & Faruqi, LLP - GlobeNewswire
Will Beta Bionics, Inc. (BBNX) report negative earnings next week? What you should know - MSN
Beta Bionics Insider Sells Over $63,000 in Stock - National Today
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Bionics (NASDAQ: BBNX) - PR Newswire
Granahan Investment Management Invests $1.7M in Beta Bionics - National Today
Top Beta Bionics Executives Quietly Cash Out in Latest Insider Moves - TipRanks
Mark Hopman Sells 2,061 Shares of Beta Bionics (NASDAQ:BBNX) Stock - MarketBeat
Beta Bionics (NASDAQ:BBNX) Insider Sells $30,073.50 in Stock - MarketBeat
Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells 856 Shares of Stock - MarketBeat
Beta Bionics (BBNX) CCO sells shares to cover RSU taxes under 10b5-1 plan - Stock Titan
Beta Bionics (BBNX) CMO sells 1,025 shares to cover RSU tax withholding - Stock Titan
Farallon Capital Management LLC Purchases 110,000 Shares of Beta Bionics, Inc. $BBNX - MarketBeat
BBNX,LYRA Options - Finviz
Beta Bionics (BBNX) grants 91,520 stock options to CPO - Stock Titan
Beta Bionics (BBNX) CMO awarded 91,520 stock options at $12.63 strike - Stock Titan
Beta Bionics (BBNX) CEO Sean Saint awarded 287,944 stock options at $12.63 - Stock Titan
Beta Bionics (BBNX) awards 91,520 stock options to Chief Commercial Officer - Stock Titan
Beta Bionics (BBNX) CFO receives grant of 110,342 stock options at $12.63 - Stock Titan
Beta BionicsSpeculative Appeal After An Eventful Start To The Year (NASDAQ:BBNX) - Seeking Alpha
Risk Check: How cyclical is Beta Bionics Incs revenue streamM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics - ChartMill
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - The Malaysian Reserve
Fed Watch: Does Beta Bionics Inc have pricing power2026 Institutional & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
BBNX,LYRA Volatility & Greeks - Finviz
Beta Bionics Earnings Call Signals Growth and Investment - TipRanks
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration - msn.com
Will Beta Bionics Inc. stock deliver consistent dividends2025 Historical Comparison & Free Fast Entry Momentum Trade Alerts - Naître et grandir
Beta Bionics reports strong preliminary Q4 2025 topline growth - MSN
Trade Recap: Why is Beta Bionics Inc stock going downWeekly Market Report & High Yield Equity Trading Tips - baoquankhu1.vn
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics - 巴士的報
Beta Bionics Details iLet Automation Strategy, Sales Expansion and Mint Patch Pump Timeline at Conference - Yahoo Finance
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics - Sahm
Beta Bionics, Inc. (NASDAQ:BBNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Mark Hopman Sells Shares of Beta Bionics Inc (BBNX) - GuruFocus
Hopman, Beta Bionics CCO, sells $4k in BBNX stock By Investing.com - Investing.com Canada
Hopman, Beta Bionics CCO, sells $4k in BBNX stock - Investing.com UK
Beta Bionics Inc Stock (BBNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beta Bionics Inc Stock (BBNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hopman Mark | Chief Commercial Officer |
Dec 02 '25 |
Sale |
29.34 |
856 |
25,112 |
138,277 |
| Russell Steven Jon | Chief Medical Officer |
Dec 02 '25 |
Sale |
29.34 |
1,025 |
30,069 |
178,071 |
| Hopman Mark | Chief Commercial Officer |
Mar 04 '26 |
Sale |
11.57 |
353 |
4,084 |
139,133 |
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):